Long-Term Benefit of Rituximab in Systemic Sclerosis A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks. https://t.co/f68wc6lQGH https://t.co/G4PKPnJ0LJ